Fox Run Management L.L.C. Takes $98,000 Position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Posted by Defense World Staff on May 8th, 2023

Fox Run Management L.L.C. purchased a new position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 28,823 shares of the company’s stock, valued at approximately $98,000.

A number of other hedge funds have also bought and sold shares of the business. Metropolitan Life Insurance Co NY raised its stake in shares of Karyopharm Therapeutics by 73.9% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 4,622 shares of the company’s stock worth $25,000 after purchasing an additional 1,964 shares during the period. Northern Trust Corp raised its position in Karyopharm Therapeutics by 0.5% in the second quarter. Northern Trust Corp now owns 768,098 shares of the company’s stock worth $3,463,000 after acquiring an additional 3,763 shares during the period. Nisa Investment Advisors LLC boosted its stake in Karyopharm Therapeutics by 612.5% in the third quarter. Nisa Investment Advisors LLC now owns 5,700 shares of the company’s stock valued at $26,000 after acquiring an additional 4,900 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Karyopharm Therapeutics by 18.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 34,397 shares of the company’s stock valued at $188,000 after acquiring an additional 5,301 shares during the period. Finally, Tudor Investment Corp Et Al increased its stake in shares of Karyopharm Therapeutics by 10.2% during the 3rd quarter. Tudor Investment Corp Et Al now owns 60,064 shares of the company’s stock worth $328,000 after purchasing an additional 5,551 shares during the last quarter. 96.13% of the stock is currently owned by institutional investors.

Insider Activity at Karyopharm Therapeutics

In related news, CEO Richard A. Paulson sold 33,033 shares of the business’s stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $3.03, for a total transaction of $100,089.99. Following the completion of the transaction, the chief executive officer now owns 823,622 shares of the company’s stock, valued at $2,495,574.66. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CFO Michael Mason sold 11,205 shares of the business’s stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $3.03, for a total transaction of $33,951.15. Following the completion of the transaction, the chief financial officer now owns 245,361 shares of the company’s stock, valued at $743,443.83. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Richard A. Paulson sold 33,033 shares of Karyopharm Therapeutics stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $3.03, for a total transaction of $100,089.99. Following the sale, the chief executive officer now owns 823,622 shares of the company’s stock, valued at $2,495,574.66. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 85,281 shares of company stock valued at $271,206. Corporate insiders own 10.24% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on KPTI. Morgan Stanley dropped their price objective on Karyopharm Therapeutics from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Friday, January 27th. HC Wainwright dropped their price target on Karyopharm Therapeutics from $16.00 to $10.00 in a research report on Friday. Robert W. Baird decreased their price objective on Karyopharm Therapeutics from $14.00 to $10.00 in a report on Friday. SVB Leerink dropped their price objective on shares of Karyopharm Therapeutics from $6.00 to $5.00 and set a “market perform” rating on the stock in a report on Tuesday, January 10th. Finally, StockNews.com initiated coverage on shares of Karyopharm Therapeutics in a research note on Thursday, March 16th. They issued a “hold” rating for the company. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Karyopharm Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $8.00.

Karyopharm Therapeutics Trading Down 2.2 %

KPTI opened at $2.71 on Monday. The firm has a 50-day moving average price of $3.59 and a 200-day moving average price of $3.81. Karyopharm Therapeutics Inc. has a twelve month low of $2.45 and a twelve month high of $6.84.

Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) last posted its earnings results on Wednesday, February 15th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.09). The firm had revenue of $33.58 million for the quarter, compared to analysts’ expectations of $33.88 million. Equities research analysts anticipate that Karyopharm Therapeutics Inc. will post -1.34 EPS for the current fiscal year.

About Karyopharm Therapeutics

(Get Rating)

Karyopharm Therapeutics, Inc is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).